Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671332 · ClinicalTrials.gov registry record · Phase 2
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT01671332 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 80 participants.
The verdict
NCT01671332, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
Interventions
- DRUG Docetaxel
- DRUG Suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671332
The ClinicalTrials.gov registry entry for NCT01671332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01671332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671332 about?
NCT01671332 is a clinical study titled "Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer". The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
What is the current status of trial NCT01671332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2012-06. Estimated completion is 2016-06-16.
What interventions are being tested in trial NCT01671332?
The interventions under investigation include: Docetaxel (DRUG), Suramin (DRUG).
Who is sponsoring clinical trial NCT01671332?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.